Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jürgen Mack is active.

Publication


Featured researches published by Jürgen Mack.


Organic Letters | 2014

Facile entry to an efficient and practical enantioselective synthesis of a polycyclic cholesteryl ester transfer protein inhibitor.

Zhengxu S. Han; Yibo Xu; Daniel R. Fandrick; Sonia Rodriguez; Zhibin Li; Bo Qu; Nina C. Gonnella; Sanjit Sanyal; Jonathan T. Reeves; Shengli Ma; Nelu Grinberg; Nizar Haddad; Dhileep Krishnamurthy; Jinhua J. Song; Nathan K. Yee; Waldemar Pfrengle; Markus Ostermeier; Jürgen Schnaubelt; Zeno A. Leuter; Sonja Steigmiller; Jürgen Däubler; Emanuel Stehle; Lukas Neumann; Thomas Trieselmann; Patrick Tielmann; Annette Buba; Rainer Hamm; Gunter Koch; Svenja Renner; Juan R. Dehli

An efficient enantioselective synthesis of the chiral polycyclic cholesteryl ester transfer protein (CETP) inhibitor 1 has been developed. The synthesis was rendered practical for large scale via the development of a modified Hantzsch-type reaction to prepare the sterically hindered pyridine ring, enantioselective hydrogenation of hindered ketone 6 utilizing novel BIBOP-amino-pyridine derived Ru complex, efficient ICl promoted lactone formation, and a BF3 mediated hydrogenation process for diastereoselective lactol reduction. This efficient route was successfully scaled to produce multikilogram quantities of challenging CETP drug candidate 1.


Journal of Natural Products | 2004

BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp.

Olivier Potterat; Klaus Wagner; Gerd Gemmecker; Jürgen Mack; Carsten Puder; Regine Vettermann; Rüdiger Streicher


Archive | 2005

Novel long-working beta-2-agonists and use thereof as medicaments

Christoph Hoenke; Klaus Rudolf; Thierry Bouyssou; Ingo Konetzki; Philipp Lustenberger; Jürgen Mack; Andreas Schnapp; Dieter Wiedenmayer


Archive | 2010

Compounds for use as bradykinin b1 antagonists

Ingo Konetzki; Angelo Ceci; Henri Doods; Norbert Hauel; Jürgen Mack; Henning Priepke; Annette Schuler-Metz; Rainer Walter


Archive | 2004

Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel

Rüdiger Streicher; Jürgen Mack; Rainer Walter; Ingo Konetzki; Thomas Trieselmann; Volkhard Austel


Archive | 2006

Substituierte pteridine zur behandlung von entzündlichen erkrankungen

Horst Dollinger; Birgit Jung; Jürgen Mack; Domnic Martyres; Peter Nickolaus


Archive | 2004

Bicyclic oligopeptides and their use as glucagon receptor antagonists

Olivier Potterat; Rüdiger Streicher; Klaus Wagner; Till Maurer; Jürgen Mack; Stefan Peters


Archive | 2010

Composés servant d'antagonistes de bradykinine b1

Ingo Konetzki; Angelo Ceci; Henri Doods; Norbert Hauel; Jürgen Mack; Henning Priepke; Annette Schuler-Metz; Rainer Walter


Archive | 2005

Nouveaux beta-2-agonistes a action longue duree et leur utilisation comme medicaments

Thierry Bouyssou; Christoph Hoenke; Ingo Konetzki; Jürgen Mack; Andreas Schnapp


Archive | 2005

Use of substituted pyrimido pyrimido[5,4-d]pyrimidines in the treatment of diseases of the respiratory tract

Peter Nickolaus; Christopher John Montague Meade; Horst Dollinger; Jürgen Mack; Georg Dahmann; Domnic Martyres; Birgit Jung

Collaboration


Dive into the Jürgen Mack's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge